Association between PIK3CA activating mutations and outcomes in early-stage invasive lobular breast carcinoma treated with adjuvant systemic therapy
, , , , , , , e
21 giu 2023
INFORMAZIONI SU QUESTO ARTICOLO
Categoria dell'articolo: Research Article
Pubblicato online: 21 giu 2023
Pagine: 220 - 228
Ricevuto: 13 feb 2023
Accettato: 18 mag 2023
DOI: https://doi.org/10.2478/raon-2023-0027
Parole chiave
© 2023 Domen Ribnikar et al., published by Sciendo
This work is licensed under the Creative Commons Attribution 4.0 International License.
Ribnikar, Domen
Department of Medical Oncology, Institute of Oncology LjubljanaLjubljana, Slovenia
Faculty of Medicine Ljubljana, University of LjubljanaLjubljana, Slovenia
Horvat, Valentina Jeric
Department of Medical Oncology, Institute of Oncology LjubljanaLjubljana, Slovenia
Ratosa, Ivica
Faculty of Medicine Ljubljana, University of LjubljanaLjubljana, Slovenia
Department of Radiation Oncology, Institute of Oncology LjubljanaLjubljana, Slovenia
Veitch, Zachary W
Division of Medical Oncology and Hematology, Royal Victoria HospitalBariie, USA
Grcar Kuzmanov, Biljana
Department of Pathology, Institute of Oncology LjubljanaLjubljana, Slovenia
Novakovic, Srdjan
Department of Molecular Diagnostics, Institute of Oncology LjubljanaLjubljana, Slovenia
Langerholc, Erik
Institute of Biostatistics and informatics, Faculty of Medicine Ljubljana, University of LjubljanaLjubljana, Slovenia
Amir, Eitan
Division of Medical Oncology and Hematology, University of Toronto and Princess Margaret Cancer CentreToronto, Canada
Seruga, Bostjan
Department of Medical Oncology, Institute of Oncology LjubljanaLjubljana, Slovenia
Faculty of Medicine Ljubljana, University of LjubljanaLjubljana, Slovenia